4Q21 Wrap: the bleeding continues

Biopharma stocks continued to spiral downwards across all market cap tiers in 4Q21. Megacaps showed the least amount of bleeding with a median loss in market cap of 5%, while microcaps lost a median of 19%.

French diagnostics player bioMerieux S.A. (Euronext:BIM) led gainers in the megacap group, defined as companies that started the quarter with valuations of $10 billion or more. The company had a 25% jump in its market cap following news that its tests can detect the Omicron variant of SARS-CoV-2...